Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Denifanstat long-term safety extension in moderate to severe acne vulgaris
NCT06248008Phase 3Completed
- Sponsor
- Ascletis Pharma Inc.
- Start
- Apr 2024
- Primary completion
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of denifanstat in acne vulgaris, sponsored by Ascletis Pharma Inc.. Started Apr 2024; status: completed.
02
Drugs
denifanstat
03
Conditions
acne vulgaris
Beyond the preview
Go deeper on NCT06248008.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06248008.